<DOC>
	<DOCNO>NCT02394015</DOCNO>
	<brief_summary>Retrospective Study Analyze Efficacy Safety Trabectedin Pegylated Liposomal Doxorubicin ( PLD ) Treatment Patients With Platinum-sensitive Recurrent Ovarian Cancer ( ROC ) , According SmPC .</brief_summary>
	<brief_title>Retrospective Study Analyze Efficacy Safety Trabectedin Pegylated Liposomal Doxorubicin ( PLD ) Treatment Patients With Platinum-sensitive Recurrent Ovarian Cancer ( ROC ) , According SmPC</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Patients receive least one dose trabectedin doxorubicin pegylated recurrent ovarian cancer accord SMPC , October 28 , 2009 October 31 , 2014 include clinical trial IMP trabectedin . Patients record unavailable ( lose , empty recoverable ) .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Platinum-sensitive Recurrent Ovarian Cancer</keyword>
</DOC>